nach oben

Zeitschrift für Rheumatologie

Erschienen in:

07.07.2022 | Entzündlich-rheumatische Erkrankungen | CME

Management von entzündlich rheumatischen Erkrankungen während und nach Malignomen

verfasst von: PD Dr. med. Marc Schmalzing

Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Management von entzündlich rheumatischen Erkrankungen bei gleichzeitiger oder stattgehabter maligner Erkrankung ist mit komplexen Fragestellungen verbunden. Schwierigkeiten und Lösungsmöglichkeiten bei der Interpretation aussagekräftiger Studien werden dargestellt. Empfehlungen in Leitlinien zu diesem Thema werden diskutiert. Nationale Register und Versicherungsdatenbanken wurden mit der Frage nach Tumorrezidivrisiko unter Basistherapeutika untersucht; diese Analysen beziehen sich aber v. a. auf TNF(Tumornekrosefaktor)-Inhibitoren und Rituximab. Zu den gängigen Substanzen der Basistherapie werden Daten zur Tumorinzidenz und – wenn vorhanden – zum Tumorrezidivrisiko zusammengefasst. Abschließend wird der Versuch unternommen, Vorschläge zur rheumatologischen Therapie bei Malignomanamnese zu formulieren.

Mercer LK, Davies R, Galloway JB, Low A, Lunt M, Dixon WG, Watson KD, Symmons DPM, Hyrich KL (2013) Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Baillieres Clin Rheumatol 52:9198

Nocturne G, Mariette X (2015) Sjögren syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 168(3):317–327PubMedCrossRef

Feldman CH, Liu J, Feldman S, Solomon DH, Kim SC (2017) Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. Lupus 26(7):682–689PubMedCrossRef

Lopez-Olivo MA, Colmegna I, Karpes Matusevich AR, Qi SR, Zamora NV, Sharma R, Pratt G, Suarez-Almazor ME (2020) Systematic review of recommendations on the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer. Arthritis Care Res (Hoboken) 72(3):309–318CrossRef

Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–639CrossRef

Singh JA, Saag KG, Bridges SL Jr et al (2016) 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68(1):1–25CrossRef

Penn I (1997) Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 2(4):14–17PubMed

Tarella C, Passera R, Magni M et al (2011) Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol 29(7):814–824PubMedCrossRef

Fraenkel L, Bathon JM, England BR, St Clair EW et al (2021) 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 73(7):924–939CrossRef

10.

Vanni KMM, Berliner N, Paynter NP, Glynn RJ, MacFadyen J, Colls J, Lu F, Xu C, Ridker PM, Solomon DH (2020) Adverse effects of low-dose methotrexate in a randomized double-blind placebo-controlled trial: adjudicated hematologic and skin cancer outcomes in the cardiovascular inflammation reduction trial. ACR Open Rheumatol 2(12):697–704PubMedPubMedCentralCrossRef

11.

Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritisc. N Engl J Med 386(4):316–326PubMedCrossRef

12.

Strangfeld A, Hierse F, Rau R et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5PubMedPubMedCentralCrossRef

13.

Dixon WG, Watson KD, Lunt M et al (2010) Influence of antitumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British society for rheumatology biologics register. Arthritis Care Res 62:755–763CrossRef

14.

Pappas DA, Rebello S, Liu M, Schenfeld J, Li Y, Collier DH, Accortt NA (2019) Therapy with biologic agents after diagnosis of solid malignancies: results from the Corrona registry. J Rheumatol 46(11):1438–1444PubMedCrossRef

15.

Dreyer L, Cordtz RL, Hansen IMJ, Kristensen LE, Hetland ML, Mellemkjaer L (2018) Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study. Ann Rheum Dis 77(4):510–514PubMedCrossRef

16.

Raaschou P, Soederling J, Turesson C, Askling J (2018) Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study. Ann Intern Med 169:291–299PubMedCrossRef

17.

Xie W, Xiao S, Huang Y, Sun X, Gao D, Ji L, Li G, Zhang Z (2020) A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy. Rheumatology (Oxford) 59(5):930–939CrossRef

18.

Shelton E, Laharie D, Scott FI et al (2016) Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 151(1):97–109.e4PubMedCrossRef

19.

Mamtani R, Clark AS, Scott FI et al (2016) Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study. Arthritis Rheumatol 68:2403–2411PubMedPubMedCentralCrossRef

20.

Schmalzing M, Strangfeld A, Tony HP (2016) Medikamentöse Therapie der rheumatoiden Arthritis bei Malignomanamnese. Epidemiologische Daten. Z Rheumatol 75:22–31PubMedCrossRef

21.

Regierer AC, Strangfeld A (2018) Rheumatoid arthritis treatment in patients with a history of cancer. Curr Opin Rheumatol 30:288–294PubMedCrossRef

22.

De Cock D, Hyrich K (2018) Malignancy and rheumatoid arthritis: epidemiology, risk factors and management. Best Pract Res Clin Rheumatol 32:869–886PubMedCrossRef

23.

Lange E, Blizzard L, Venn A, Francis H, Jones G (2016) Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study. Rheumatology (Oxford) 55(9):1594–1600CrossRef

24.

Rizzi R, Curci P, Delia M, Rinaldi E, Chiefa A, Specchia G, Liso V (2009) Spontaneous remission of „methotrexate-associated lymphoproliferative disorders“ after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 26(1):1–9PubMedCrossRef

25.

Hellgren K, Baecklund E, Backlin C et al (2017) Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased? Arthritis Rheumatol 69(4):700–708PubMedCrossRef

26.

Behrens F, Koehm M, Burkhardt H (2011) Update 2011: leflunomide in rheumatoid arthritis—strengths and weaknesses. Curr Opin Rheumatol 23(3):282–287PubMedCrossRef

27.

Ruiz-Irastorza G, Ugarte A, Egurbide MV, Garmendia M, Pijoan JI, Martinez-Berriotxoa A, Aguirre C (2007) Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 66(6):815–817PubMedPubMedCentralCrossRef

28.

Fardet L, Nazareth I, Petersen I (2017) Effects of chronic exposure of hydroxychloroquine/chloroquine on the risk of cancer, metastasis, and death: a population-based cohort study on patients with connective tissue diseases. Clin Epidemiol 9:545–554PubMedPubMedCentralCrossRef

29.

Lopez A, Pouillon L, Beaugerie L, Danese S, Peyrin-Biroulet L (2018) Colorectal cancer prevention in patients with ulcerative colitis. Best Pract Res Clin Gastroenterol 32–33:103–109PubMedCrossRef

30.

Moore TJ Safety perspectives: cancer risks of biological products for psoriasis. https://www.ismp.org/quarterwatch/safety-perspectives. Zugegriffen: 29. März 2018

31.

Thai A, Prindiville T (2010) Hepatosplenic T‑cell lymphoma and inflammatory bowel disease. J Crohns Colitis 4:511–522PubMedCrossRef

32.

Ertz-Archambault N, Kosiorek H, Taylor GE et al (2017) Association of therapy for autoimmune disease with myelodysplastic syndromes and acute myeloid leukemia. JAMA Oncol 3(7):936–943PubMedPubMedCentralCrossRef

33.

Scott FI, Mamtani R, Brensinger CM et al (2016) Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol 152(2):164–172PubMedPubMedCentralCrossRef

34.

Muellenhoff MW, Koo JY (2012) Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. J Dermatolog Treat 23(4):290–304PubMedCrossRef

35.

Vos M, Plasmeijer EI, van Bemmel BC et al (2018) Azathioprine to mycophenolate mofetil transition and risk of squamous cell carcinoma after lung transplantation. J Heart Lung Transplant 37(7):853–859PubMedCrossRef

36.

Hellbacher E, Hjorton K, Backlin C et al (2019) Malignant lymphoma in granulomatosis with polyangiitis: subtypes, clinical characteristics and prognosis. Acta Oncol 58(11):1655–1659PubMedCrossRef

37.

Kang KY, Kim HO, Yoon HS et al (2010) Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol 29(4):381–388PubMedCrossRef

38.

Raaschou P, Simard JF, Asker Hagelberg C, Askling J (2016) Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ 352:i262PubMedPubMedCentralCrossRef

39.

Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh A, Canhao H, Iannone F, Zavada J, Morel J, Gottenberg JE, Hyrich KL, Listing J (2017) Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis 76(2):386–391PubMedCrossRef

40.

Staples MP, March L, Hill C, Lassere M, Buchbinder R (2019) Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian rheumatology association database (ARAD) prospective cohort study. BMC Rheumatol 3:1PubMedPubMedCentralCrossRef

41.

Cordtz R, Mellemkjær L, Glintborg B, Hetland ML, Dreyer L (2015) Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with arthritis. Ann Rheum Dis 74(7):1479–1480PubMedCrossRef

42.

Calip GS, Patel PR, Adimadhyam S, Xing S, Wu Z, Sweiss K, Schumock GT, Lee TA, Chiu BC (2018) Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. Int J Cancer 143(5):1062–1071PubMedPubMedCentralCrossRef

43.

Mercer LK, Galloway JB, Lunt M et al (2017) Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis 76(3):497–503PubMedCrossRef

44.

Perez-Ruiz E, Minute L, Otano I et al (2019) Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA‑4 and PD‑1 immunotherapy. Nature 569(7756):428–432PubMedCrossRef

45.

Bertrand F, Montfort A, Marcheteau E et al (2017) TNFα blockade overcomes resistance to anti-PD‑1 in experimental melanoma. Nat Commun 8(1):2256PubMedPubMedCentralCrossRef

46.

Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M (2019) Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer 7(1):226PubMedPubMedCentralCrossRef

47.

Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, Johnson DH, Uemura M, Diab A (2017) Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis 76(12):2061–2064PubMedCrossRef

48.

Kim SC, Pawar A, Desai RJ, Solomon DH, Gale S, Bao M, Sarsour K, Schneeweiss S (2019) Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum 49(2):222–228PubMedCrossRef

49.

Wadström H, Frisell T, Askling J (2017) Anti-rheumatic therapy in Sweden (ARTIS) study group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, Tocilizumab, Abatacept, or Rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med 177(11):1605–1612PubMedPubMedCentralCrossRef

50.

Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, Hochberg MC, Reed G, Tsao P, Greenberg JD (2014) Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 43(4):489–497PubMedCrossRef

51.

Montastruc F, Renoux C, Dell’Aniello S, Simon TA, Azoulay L, Hudson M, Suissa S (2019) Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. Rheumatology (Oxford) 58(4):683–691CrossRef

52.

Redeker I, Herzer P, Kühne C, Schwarze I, Schaefer M, Strangfeld A (2021) Occurrence of basal cell and squamous cell carcinomas of the skin under different DMARD therapies [abstract]. Arthritis Rheumatol 73(suppl 10). https://acrabstracts.org/abstract/occurrence-of-basal-cell-and-squamous-cell-carcinomas-of-the-skin-under-different-dmard-therapies/. Zugegriffen: 30.06.2022

53.

de Germay S, Bagheri H, Despas F, Rousseau V, Montastruc F (2020) Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. Rheumatology (Oxford) 59(9):2360–2367CrossRef

54.

Nast A, Amelunxen L, Augustin M et al (2017) S3-Leitlinie zur Therapie der Psoriasis vulgaris (AWMF-Register Nr. 013/001)

55.

Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, Goyal K, Langholff W, Fakharzadeh S, Srivastava B, Langley RG (2017) Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry. J Am Acad Dermatol 77(5):845–854.e5PubMedCrossRef

56.

Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ (2017) Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390(10105):1833–1842PubMedCrossRef

57.

Porpaczy E, Tripolt S, Hoelbl-Kovacic A et al (2018) Aggressive B‑cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood 132(7):694–706PubMedCrossRef

58.

Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S (2019) Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood 133(21):2348–2351PubMedPubMedCentralCrossRef

59.

Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, Burmester GR (2021) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 80(3):304–311PubMedCrossRef

60.

Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Riddle Camp J, Cardillo TE, Ishii T, Winthrop KL (2019) Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 46(1):7–18PubMedCrossRef

61.

Kremer JM, Bingham CO 3rd, Cappelli LC, Greenberg JD, Madsen AM, Geier J, Rivas JL, Onofrei AM, Barr CJ, Pappas DA, Litman HJ, Dandreo KJ, Shapiro AB, Connell CA, Kavanaugh A (2021) Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5‑year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol 3(3):173–184PubMedPubMedCentralCrossRef

Titel: Management von entzündlich rheumatischen Erkrankungen während und nach Malignomen
verfasst von: PD Dr. med. Marc Schmalzing
Publikationsdatum: 07.07.2022
Verlag: Springer Medizin
Schlagwörter: Entzündlich-rheumatische Erkrankungen
Rituximab
Rituximab
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe 9/2022
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-022-01237-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Management von entzündlich rheumatischen Erkrankungen während und nach Malignomen

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2022

The Genesis of Sjögren

Mitteilungen der DGRh

Mitteilungen der DGRh - Veranstaltungen der Rheumaakademie

Das VEXAS-Syndrom – eine seltene Erkrankung im fortgeschrittenen Erwachsenenalter

Relationship of complement activation pathway to clinical and pathological characteristics and renal outcome in patients with lupus nephritis

Leitfaden „Geschlechtergerechte Sprache in der DGRh e. V.“

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Denken Sie bei starker Blutung auch an die Hemmkörper-Hämophilie

Update Innere Medizin

Leitfaden „Geschlechtergerechte Sprache in der DGRh e. V.“